Guiying Wang

Guiying Wang

Auto-generated profile, based on publicly available information

Guiying Wang

Clinical and Translational Research Center of Shanghai First Maternity and Infant Hospital, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Key Laboratory of Signaling and Disease Research, Frontier Science Center for Stem Cell Research, National Stem Cell Translational Resource Center, School of Life Sciences and Technology, Tongji University, Shanghai, China

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2017 in Stem Cells
Verified
Journal Article
Open access
PDF file
RWRong Weng
Rong Weng
CLChenqi Lu
Chenqi Lu
XLXiaoqin Liu
Xiaoqin Liu
GLGuoping Li
Guoping Li
YLYuanyuan Lan
Yuanyuan Lan
JKJiuhong Kang
Jiuhong Kang
Clarifying the regulatory mechanisms of embryonic stem cell (ESC) neural differentiation is helpful not only for understanding neural development but also for obtaining high-quality neural progenitor cells required by stem cell therapy of neurodegenerative diseases. Here, we found that long noncoding RNA 1604 (lncRNA-1604) was highly expressed in cytoplasm during neural differentiation, and knockdown of lncRNA-1604 significantly repressed neural differentiation of mouse ESCs both in vitro and in vivo. Bioinformatics prediction and mechanistic analysis revealed that lncRNA-1604 functioned as a novel competing endogenous RNA of miR-200c and regulated the core transcription factors ZEB1 and ZEB2 during neural differentiation. Furthermore, we also demonstrated the critical role of miR-200c and ZEB1/2 in mouse neural differentiation. Either introduction of miR-200c sponge or overexpression of ZEB1/2 significantly reversed the lncRNA-1604 knockdown-induced repression of mouse ESC neural differentiation. Collectively, these findings not only identified a previously unknown role of lncRNA-1604 and ZEB1/2 but also elucidated a new regulatory lncRNA-1604/miR-200c/ZEB axis in neural differentiation.

20 November 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
GFGuobiao Fan
Guobiao Fan
DYDan Ye
Dan Ye
SZSongcheng Zhu
Songcheng Zhu
JXJiajie Xi
Jiajie Xi
XGXudong Guo
Xudong Guo
JKJiuhong Kang
Jiuhong Kang
RTL1 promotes melanoma proliferation by regulating Wnt/-catenin signalling RTL1 promotes melanoma proliferation by regulating Wnt/β-catenin signalling

24 January 2013 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
YWYuping Wang
Yuping Wang
JCJie Chen
Jie Chen
LWLin Wang
Lin Wang
YHYuji Huang
Yuji Huang
YLYe Leng
Ye Leng
GWGuiying Wang
Guiying Wang
Chronic myeloid leukemia (CML) is a hematopoietic stem cell disease caused by the oncoprotein BCR-ABL, which exhibits a constitutive tyrosine kinase activity. Imatinib mesylate (IM), an inhibitor of the tyrosine kinase activity of BCR-ABL, has been used as a first-line therapy for CML. However, IM is less effective in the accelerated phase and blastic phases of CML and certain patients develop IM resistance due to the mutation and amplification of the BCR-ABL gene. Fangchinoline, an important chemical constituent from the dried roots of Stephaniae tetrandrae S. Moore, exhibits significant antitumor activity in various types of cancers, including breast, prostate and hepatocellular carcinoma. However, the effects and the underlying mechanisms of fangchinoline in CML remain unclear. In the present study, we identified that fangchinoline inhibits cell proliferation in a dose- and time-dependent manner in K562 cells derived from the blast crisis of CML. Additional experiments revealed that fangchinoline induces cell cycle arrest at the G0/G1 phase and has no effect on apoptosis, which is mediated through the upregulation of cyclin-dependent kinase (CDK)-N1A and MCL-1 mRNA levels, as well as the downregulation of cyclin D2 (CCND2) mRNA levels. These findings suggest the potential of fangchinoline as an effective antitumor agent in CML.

28 January 2020 in Clinical and Translational Medicine
Verified
Journal Article
Open access
PDF file
GWGuiying Wang
Guiying Wang
JYJun Yu
Jun Yu
YYYiwei Yang
Yiwei Yang
XLXiaoqin Liu
Xiaoqin Liu
XZXiaobo Zhao
Xiaobo Zhao
JKJiuhong Kang
Jiuhong Kang
Background: Fetal growth restriction (FGR) contributes the primary cause of perinatal mortality and morbidity with impacts on the long‐term health. To determine the core gene expression network and gene signatures, which in combination with ultrasound confirmation will more effectively differentiate constitutionally normal small for gestational age and pathological FGR groups, we performed RNA sequencing for protein‐coding genes, lncRNAs, and small RNAs in a case–control study of umbilical cord blood.Results: Five pairs of FGR case and control umbilical cord blood samples were used for RNA sequencing and weighted gene co‐expression network analysis (WGCNA). Results showed that 339 mRNAs, 295 lncRNAs, and 13 miRNAs were significantly differentially expressed between FGR cases and controls. Bioinformatics analysis indicated that these differentially expressed molecules were mainly involved in metabolism, neural, cardiac, and immune systems, and identified 18 WGCNA modules for FGR. Further quantitative verification was performed using umbilical cord blood and maternal peripheral blood from 12 pairs of FGR cases and controls. The logistic regression and receiver operating characteristic curve indicated that RP11_552M6.1, LINC01291, and Asgr1 in umbilical cord blood, while Sfrp2, miR‐432‐5p, and miR‐1306‐3p in maternal peripheral blood had potential significance for FGR.Conclusions: We comprehensively profiled the whole‐transcriptome landscape of human umbilical cord blood with FGR, constructed the core WGCNA modules, and delineated the critical gene signatures of FGR. These findings provide key insight into intrauterine perturbations and candidate signatures for FGR.

1 August 2011
Verified
Journal Article
Closed access
LZLei Zhang
Lei Zhang
GWGuiying Wang
Guiying Wang
LWLin Wang
Lin Wang
CSChenlin Song
Chenlin Song
XWXinhua Wang
Xinhua Wang
JKJiuhong Kang
Jiuhong Kang

30 September 2020 in Stem Cells
Verified
Journal Article
Closed access
PDF file
XLXiaoqin Liu
Xiaoqin Liu
YYYiwei Yang
Yiwei Yang
XWXing Wang
Xing Wang
XGXudong Guo
Xudong Guo
CLChenqi Lu
Chenqi Lu
GWGuiying Wang
Guiying Wang